Displaying 81 - 100 of 113
Baxter International Inc., Claris Lifesciences Limited, and Arjun Handa, In the Matter of
Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle charges that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business would (1) reduce current competition in the United States for the antifungal agent fluconazole in saline intravenous bags, which is used to treat fungal and yeast infections, and (2)reduce future competition in the U.S. market for intravenous milrinone, which dilates the blood vessels, lowers blood pressure and allows blood to flow more easily through the cardiovascular system. Under the FTC order, the parties will divest all of Claris’s rights to fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags to New Jersey-based pharmaceutical company Renaissance Lakewood LLC. The order requires Baxter to supply Renaissance with fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags for up to five years while transferring the manufacturing technology to Renaissance or its contract manufacturing designee. Baxter is also required to assist Renaissance in establishing its manufacturing capabilities and securing the necessary FDA approvals.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
171 0052
Prepared Statement of the Federal Trade Commission on "Antitrust Concerns and the FDA Approval Process,” Before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Judiciary Committee, United States House of Representatives
Date
By
Markus H. Meier, Acting Director, Bureau of Competition
Matter Number
P859900
File
Text of the Commission Testimony
(101.52 KB)
FTC Testifies before House Judiciary Committee’s Subcommittee on Regulatory Reform, Commercial and Antitrust Law about Antitrust Concerns and the FDA Approval Process
Date
In testimony presented to the U.S. House of Representatives’ Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to...
FTC Requires Baxter International and Claris Lifesciences to Divest 2 Types of Pharmaceutical Products as Condition of Baxter Acquiring Injectable Drugs Business from Claris
Date
Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle Federal Trade Commission charges that Baxter’s proposed $625 million...
Federal Trade Commission Approves Appointment of Monitor in Pay-for-Delay Case against Endo Pharmaceuticals Inc.
Date
The Federal Trade Commission has approved the appointment of Quantic Regulatory Services, LLC as monitor in its case alleging that Endo Pharmaceuticals Inc. violated antitrust laws by using pay-for...
FTC Requests Public Comment on Application from Grifols, S.A. to Amend Contract Manufacturing Agreement that was part of 2011 Divestiture Ordered by the Agency
Date
The Federal Trade Commission is currently accepting public comments on an application by Grifols, S.A., a manufacturer of plasma-derived drugs, to amend the terms of a manufacturing agreement that was...
FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm
Date
The Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay...
FTC Report on Drug Patent Settlements Shows Potential Pay-for-Delay Deals Decreased Substantially in the First Year Since Supreme Court’s Actavis Decision
Date
Pharmaceutical companies entered into substantially fewer potential pay-for-delay patent dispute settlements in fiscal year 2014, according to a new FTC staff report. The report summarizes data on...
FTC Approves Final Order Preserving Competition in the U.S. Markets for Generic Drugs to Treat Certain Types of Ulcers, and Thyroid Conditions
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the $8 billion merger between Endo International plc and Par Pharmaceuticals, Inc...
FTC Requires Divestitures in Connection with Endo International plc’s Proposed Acquisition of Par Pharmaceuticals, Inc.
Date
Pharmaceutical companies Endo International plc and Par Pharmaceuticals, Inc. have agreed to divest all of Endo’s rights and assets to generic glycopyrrolate tablets and generic methimazole tablets in...
Statement of the Federal Trade Commission FTC v. Cephalon, Inc.
Date
By
Edith Ramirez, Former Chairwoman;
Julie Brill, Former Commissioner;
Terrell McSweeny, Former Commissioner
FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics
Date
Related private monetary settlements may be credited against FTC fund
FTC Puts Conditions on Eli Lilly’s Proposed Acquisition of Novartis Animal Health
Date
Global pharmaceutical company Eli Lilly and Company has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs in order to settle FTC charges that its...
FTC Puts Conditions on Pharmaceutical Joint Venture Between GlaxoSmithKline and Novartis
Date
Global pharmaceutical company Novartis AG has agreed to divest Habitrol, its nicotine replacement therapy patch, to settle FTC charges that its consumer health care products joint venture with...
FTC Seeks Public Comments on Proposed Amendments to the Premerger Notification Rules Related to the Transfer of Exclusive Patent Rights in the Pharmaceutical Industry
Date
The Federal Trade Commission is seeking public comments on proposed changes to the premerger notification rules that could require companies in the pharmaceutical industry to report proposed...
FTC Testifies Before House Judiciary Subcommittee on Agency's Work to Promote Competition and Benefit Consumers
Date
In testimony today before a U.S. House of Representatives Judiciary Subcommittee, the Federal Trade Commission detailed its work to promote competition and benefit consumers, including preventing...
Displaying 81 - 100 of 113